BHBjörn-Thore Hansen

Björn-Thore Hansen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Björn-Thore Hansen has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Alina M. Hartmann

    Medical Department II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany

    1 shared publication
  • Björn Brändl

    Department of Psychiatry and Psychotherapy, Christian-Albrechts Universität

    1 shared publication
  • Björn Steffen

    10Department of Medicine II, Hematology/Oncology, Goethe University Frankfurt, University Hospital, Frankfurt, Germany

    1 shared publication
  • Christian Rohrandt

    Department of Psychiatry and Psychotherapy, Christian-Albrechts Universität

    1 shared publication
  • Christoph Faul

    12Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tübingen, Germany

    1 shared publication
  • Claudia D. Baldus

    Medical Department II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany

    1 shared publication

Latest Publications

  • Open Access

    Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL

    by Lorenz Bastian, Thomas Beder, Malwine J. Barz, Sonja Bendig, Lorenz Bartsch, Wencke Walter, Nadine Wolgast, Björn Brändl, Christian Rohrandt, Björn-Thore Hansen, et al.

    Distinct diagnostic entities within BCR::ABL1-positive acute lymphoblastic leukemia (ALL) are currently defined by the International Consensus Classification of myeloid neoplasms and acute leukemias (ICC): “lymphoid only”, with BCR::ABL1 observed exclusively in lymphatic precursors, vs “multilineage”, where BCR::ABL1 is also present in other hematopoietic lineages. Here, we analyzed transcriptomes of 327 BCR::ABL1-positive patients with ALL (age, 2-84 years; median, 46 years) and identified 2 main gene expression clusters reproducible across 4 independent patient cohorts. Fluorescence in situ hybridization analysis of fluorescence-activated cell-sorted hematopoietic compartments showed distinct BCR::ABL1 involvement in myeloid cells for these clusters (n = 18/18 vs n = 3/16 patients; P < .001), indicating that a multilineage or lymphoid BCR::ABL1 subtype can be inferred from gene expression. Further subclusters grouped samples according to cooperating genomic events (multilineage: HBS1L deletion or monosomy 7; lymphoid: IKZF1-/- or CDKN2A/PAX5 deletions/hyperdiploidy). A novel HSB1L transcript was highly specific for BCR::ABL1 multilineage cases independent of HBS1L genomic aberrations. Treatment on current German Multicenter Study Group for Adult ALL (GMALL) protocols resulted in comparable disease-free survival (DFS) for multilineage vs lymphoid cluster patients (3-year DFS: 70% vs 61%; P = .530; n = 91). However, the IKZF1-/- enriched lymphoid subcluster was associated with inferior DFS, whereas hyperdiploid cases showed a superior outcome. Thus, gene expression clusters define underlying developmental trajectories and distinct patterns of cooperating events in BCR::ABL1-positive ALL with prognostic relevance.